• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Capstone Holding Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    11/28/25 3:10:47 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPS alert in real time by email
    false 0000887151 0000887151 2025-11-28 2025-11-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): November 28, 2025

     

    CAPSTONE HOLDING CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33560   86-0585310

    (State or other jurisdiction

    of incorporation)

      (Commission File Number)  

    (I.R.S. Employer

    Identification No.)

     

    5141 W. 122nd Street

    Alsip, IL 60803

    (Address of principal executive offices)

     

    Registrant’s telephone number, including area code: (708) 371-0660

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0005 per share   CAPS   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    As previously disclosed, on July 29, 2025, Capstone Holding Corp. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Buyer”), pursuant to which the Company authorized the issuance of senior secured convertible notes to the Buyer, in the aggregate original principal amount of up to $10,909,885, which are being issued with a 8.34% original issue discount (each, a “Convertible Note”). The first Convertible Note was issued in the original principal amount of approximately $3,272,966 (the “July 2025 Convertible Note”), and the second Convertible Note was issued in the original principal amount of approximately $3,545,712.42 (the “October 2025 Convertible Note”, and together with the July 2025 Convertible Note, the “Notes”). The Convertible Notes are convertible into shares of common stock, $0.0005 par value per share (the “Common Stock”) in certain circumstances in accordance with the terms of the Convertible Notes, with the July 2025 Convertible Note having an initial conversion price per share of $1.72 (subsequently reduced to $1.00) and the October 2025 Convertible Note having a conversion price of $1.10 (the “Conversion Price)”.

     

    Pursuant to the effective registration statements on Form S-1 (File Nos. 333-289222 and 333-291041), the Company registered a total of 8,388,336 shares of Common Stock issuable upon conversion of the Convertible Notes.

     

    On November 28, 2025, pursuant to Section 7(h) of the Notes, the Company and the Buyer agreed, pursuant to a Conversion Price Voluntary Adjustment Notice signed by both parties, to reduce the Conversion Price to $0.75 with regard to the entire amount of the July 2025 Convertible Note still owed in the principal amount $500,744.01, and with regard to $1,772,856.21 of the principal amount of the October 2025 Convertible Note (with $1,772,856.21 of the principal balance of the October 2025 Convertible Note still having a $1.10 conversion price).

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit

    Number

      Exhibits
    10.1   Conversion Price Voluntary Adjustment Notice
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 28, 2025 Capstone Holding Corp.
         
      By: /s/ Matthew E. Lipman
      Name:  Matthew E. Lipman
      Title: Chief Executive Officer

     

     

    2

     

    Get the next $CAPS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CAPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Schultz Edward Christopher

    3 - Capstone Holding Corp. (0000887151) (Issuer)

    4/22/25 3:55:58 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Lipman Matthew E. claimed ownership of 2,650,436 shares (SEC Form 3)

    3 - Capstone Holding Corp. (0000887151) (Issuer)

    4/22/25 3:53:49 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Holliman John M Iii claimed ownership of 1,095 shares (SEC Form 3)

    3 - Capstone Holding Corp. (0000887151) (Issuer)

    4/14/25 7:04:52 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CAPS
    SEC Filings

    View All

    Capstone Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Capstone Holding Corp. (0000887151) (Filer)

    12/15/25 7:30:43 AM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capstone Holding Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Capstone Holding Corp. (0000887151) (Filer)

    12/2/25 8:20:42 AM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Capstone Holding Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Capstone Holding Corp. (0000887151) (Filer)

    11/28/25 3:10:47 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care